Moreover, in the event that asymptomatic individuals carrying NPC1/2 mutations will be affected by AD, it is postulated that the use of miglustat, which is often suggested for the treatment of NPC and Gaucher disease type 1, may be a viable approach to consider [11]. The gene discussed is NPC1; the disease is Alzheimer disease.